What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
作者信息
Palatnik-de-Sousa Clarisa B
机构信息
Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Institute for Research in Immunology, Faculty of Medicine, University of São Paulo (USP), São Paulo, Brazil.
出版信息
Front Immunol. 2020 Aug 26;11:2173. doi: 10.3389/fimmu.2020.02173. eCollection 2020.
Abstract
摘要
相似文献
1
What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.詹纳和巴斯德会如何应对新冠冠状病毒？一位疫苗学家的呼吁。
Front Immunol. 2020 Aug 26;11:2173. doi: 10.3389/fimmu.2020.02173. eCollection 2020.
2
Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.在严重急性呼吸综合征冠状病毒2疫苗研发中平衡权宜性与科学严谨性
J Infect Dis. 2020 Jun 29;222(2):180-182. doi: 10.1093/infdis/jiaa234.
3
SARS-CoV-2 immunogenicity at the crossroads.十字路口的新型冠状病毒2型免疫原性
Allergy. 2020 Jul;75(7):1822-1824. doi: 10.1111/all.14360. Epub 2020 May 25.
4
Coronavirus vaccines get a biotech boost.冠状病毒疫苗获得生物技术助力。
Nature. 2020 Jul;583(7817):647-649. doi: 10.1038/d41586-020-02154-2.
5
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.2020 年大流行：当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
6
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.DNA 疫苗对食蟹猴 SARS-CoV-2 的保护作用。
Science. 2020 Aug 14;369(6505):806-811. doi: 10.1126/science.abc6284. Epub 2020 May 20.
7
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.昆虫细胞表达的 SARS-CoV-2 刺突蛋白可在非人灵长类动物中引起高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090. doi: 10.1080/22221751.2020.1821583.
8
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
9
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果：两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.
10
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
引用本文的文献
1
Cross-protection induced by highly conserved human B, CD4, and CD8 T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern.基于高度保守的人类B细胞、CD4和CD8 T细胞表位的疫苗诱导的交叉保护作用，可抵御由多种值得关注的SARS-CoV-2变体引起的严重感染、疾病和死亡。
Front Immunol. 2024 Jan 22;15:1328905. doi: 10.3389/fimmu.2024.1328905. eCollection 2024.
2
A novel vaccine based on SARS-CoV-2 CD4 and CD8 T cell conserved epitopes from variants Alpha to Omicron.基于 SARS-CoV-2 变异株 Alpha 至奥密克戎的 CD4 和 CD8 T 细胞保守表位的新型疫苗。
Sci Rep. 2022 Oct 6;12(1):16731. doi: 10.1038/s41598-022-21207-2.
3
COVID-19 Vaccines and Autoimmune Hematologic Disorders.2019冠状病毒病疫苗与自身免疫性血液系统疾病
Vaccines (Basel). 2022 Jun 16;10(6):961. doi: 10.3390/vaccines10060961.
4
Designing a Recombinant Vaccine against Using Immunoinformatics Approach.使用免疫信息学方法设计一种针对……的重组疫苗。 （原文中“against”后缺少具体对象）
Vaccines (Basel). 2022 Jan 25;10(2):189. doi: 10.3390/vaccines10020189.
5
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.聚焦于现有 COVID-19 疫苗的技术、机制、安全性和有效性的综述。
Int Immunopharmacol. 2021 Nov;100:108162. doi: 10.1016/j.intimp.2021.108162. Epub 2021 Sep 17.
本文引用的文献
1
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.ChAdOx1 nCoV-19 疫苗可预防恒河猴的 SARS-CoV-2 肺炎。
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
2
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的安全性和免疫原性：一项 1/2 期、单盲、随机对照临床试验的初步报告。
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
3
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
4
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
5
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.COVID-19 患者体内诱导中和抗体的 SARS-CoV-2 刺突蛋白上的两个线性表位。
Nat Commun. 2020 Jun 1;11(1):2806. doi: 10.1038/s41467-020-16638-2.
6
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.一种基于重组腺病毒 5 型的 COVID-19 疫苗的安全性、耐受性和免疫原性：一项剂量递增、开放标签、非随机、首次人体试验。
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
7
Coronavirus vaccine trials have delivered their first results - but their promise is still unclear.冠状病毒疫苗试验已得出首批结果——但其前景仍不明朗。
Nature. 2020 May;581(7809):363-364. doi: 10.1038/d41586-020-01092-3.
8
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
9
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
10
SARS-CoV-2: Structural diversity, phylogeny, and potential animal host identification of spike glycoprotein.SARS-CoV-2：刺突糖蛋白的结构多样性、系统发育和潜在动物宿主鉴定。
J Med Virol. 2020 Sep;92(9):1690-1694. doi: 10.1002/jmv.25976. Epub 2020 May 17.
Zotero 插件